# Inthera Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inthera-bioscience

- Industry: Pharmaceuticals
- Headquarters: Zurich, Switzerland
- Website: www.intherabio.com
- Total disclosed funding: $20M
- Latest round: Series A (Jul 2, 2018)
- Investors on record: 4

## About

Inthera Bioscience AG is a biopharmaceutical company dedicated to developing innovative therapies aimed at treating currently incurable cancers through selective targeting of cancer cells.Founded in 2013 and headquartered in Zurich, Switzerland, Inthera Bioscience AG specializes in creating novel cancer therapies. The company has engaged in three significant funding rounds, with the most recent being a Series A round completed in July 2018, where they raised EUR 9.6 million from investors including Aglaia Oncology Funds, M Ventures, and Novo Seeds.Inthera Bioscience focuses on developing advanced biopharmaceuticals that target cancer cells by inducing replicative stress. Their innovative therapies are designed to disrupt the cancer cell cycle, improving outcomes for patients with various types of cancer. The company primarily collaborates with hospitals, oncology clinics, and research institutions across North America and Europe.Inthera Bioscience’s revenue model is primarily based on collaborative partnerships and clinical trials, generating income through licensing agreements and partnerships with healthcare institutions and pharmaceutical companies. The revenue includes potential streams from collaborative research agreements and milestone payments tied to achieving specific clinical or regulatory milestones.Following their EUR 9.6 million Series A funding round in July 2018, Inthera Bioscience AG aims to leverage these resources to advance their therapeutic innovations. The company plans to develop new products targeting critical cancer pathways and expand into additional markets in Europe and North America by 2023, focusing on addressing substantial unmet needs in cancer treatment.

## Funding rounds

- Series A, Jul 2, 2018, $11M — M Ventures, Aglaia Oncology Funds, Novo Seeds
- Series A, May 31, 2017, $5.5M — M Ventures, Aglaia Oncology Funds, Novo Seeds
- Seed, Dec 15, 2015, $3.7M — M Ventures, Aglaia Oncology Funds, EVA, Novo Seeds

## Investors

- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Seed, Series A
- Aglaia Oncology Funds (https://capitalatlas.ai/funds/aglaia-oncology-funds) — Seed, Series A
- EVA (https://capitalatlas.ai/funds/eva) — Seed
- Novo Seeds — Seed, Series A